Our name might give you the impression that we specialize only in oncogenes. As you can clearly see, our product line goes well beyond oncogenes. And even this extensive listing is only a fraction of our total line! We have cytoskeletal protein products, hematopoietic factor products, cytokines, interleukins, DNA tumor virus antibodies, cell adhesion antibodies, cardiovascular reagents, and products for neuroscience research. If you don't see what you need for your research, just give us a call at 800-662-2616 from anywhere in the continental US (NY included) or at 516-222-0023 from outside the US.
**The SOURCE™**

for over 1,000 Antibodies, Probes, ELISA’s, and the Reagents to Make Them Work!

<table>
<thead>
<tr>
<th>Cell Cycle Products</th>
<th>p53/Tumor Suppressor Genes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cyclin A</td>
<td>p53 wild-type</td>
</tr>
<tr>
<td>WB IP</td>
<td>IP</td>
</tr>
<tr>
<td>Cyclin B&lt;sub&gt;1&lt;/sub&gt;</td>
<td>mutant</td>
</tr>
<tr>
<td>WB IP</td>
<td>CS</td>
</tr>
<tr>
<td>p-13&lt;sup&gt;sup-1&lt;/sup&gt;</td>
<td>pantropic</td>
</tr>
<tr>
<td>IP</td>
<td>ELISA</td>
</tr>
<tr>
<td>PCNA</td>
<td>Rb</td>
</tr>
<tr>
<td>PS WB IP CS SH</td>
<td>WB IP</td>
</tr>
<tr>
<td>p34&lt;sup&gt;cdc-2&lt;/sup&gt;</td>
<td>DCC</td>
</tr>
<tr>
<td>WB IP CS</td>
<td>WB IP</td>
</tr>
<tr>
<td>raf-1</td>
<td>APC</td>
</tr>
<tr>
<td>WB IP CS</td>
<td>ELISA</td>
</tr>
<tr>
<td>PSTAIRE</td>
<td>Wilm’s</td>
</tr>
<tr>
<td>WB IP CS</td>
<td>Coming Soon!</td>
</tr>
<tr>
<td>Protein Kinase C</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Signal Transduction</th>
<th>Oncogenes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Phosphotyrosine</td>
<td>erb-B2 (neu)</td>
</tr>
<tr>
<td>PS WB IP CS</td>
<td>PS WB IP CS SH ELISA</td>
</tr>
<tr>
<td>src</td>
<td>v-H-ras</td>
</tr>
<tr>
<td>WB IP Enzyme</td>
<td>PS WB IP CS SH</td>
</tr>
<tr>
<td>fyn</td>
<td>c-H-ras</td>
</tr>
<tr>
<td>CS</td>
<td>PS WB IP CS SH</td>
</tr>
<tr>
<td>c-abl</td>
<td>c-K-ras</td>
</tr>
<tr>
<td>WB IP CS</td>
<td>PS WB IP CS SH</td>
</tr>
<tr>
<td>PTPases</td>
<td>c-N-ras</td>
</tr>
<tr>
<td>WB IP CS</td>
<td>PS WB IP CS SH</td>
</tr>
<tr>
<td>trk</td>
<td>pantropic ras</td>
</tr>
<tr>
<td>WB IP</td>
<td>ELISA</td>
</tr>
<tr>
<td>Mutation-Specific ras Antibodies</td>
<td>Asp&lt;sub&gt;12&lt;/sub&gt;, Arg&lt;sub&gt;12&lt;/sub&gt;, Glu&lt;sub&gt;12&lt;/sub&gt;, Val&lt;sub&gt;12&lt;/sub&gt;</td>
</tr>
<tr>
<td>ELISA</td>
<td>Coming Soon!</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Transcription Factors</th>
<th>Growth Factors / Receptors</th>
</tr>
</thead>
<tbody>
<tr>
<td>c-fos</td>
<td>TGFα</td>
</tr>
<tr>
<td>PS WB IP CS SH</td>
<td>PS WB IP CS SH ELISA</td>
</tr>
<tr>
<td>c-jun / AP–1</td>
<td>TGFβ</td>
</tr>
<tr>
<td>PS WB IP CS SH</td>
<td>IP WB SH</td>
</tr>
<tr>
<td>jun B</td>
<td>bFGF</td>
</tr>
<tr>
<td>PS WB IP CS SH</td>
<td>WB SH</td>
</tr>
<tr>
<td>c-myc</td>
<td>PDGF</td>
</tr>
<tr>
<td>WB IP CS</td>
<td>SH</td>
</tr>
<tr>
<td>N myc</td>
<td>EGFR</td>
</tr>
<tr>
<td>WB IP CS</td>
<td>ELISA</td>
</tr>
</tbody>
</table>

All products except TransProbe-1™ are for research use only. Not for use in diagnostic or therapeutic procedures.

Call for more information—1-800-662-2616

Oncogene Science™

106 Charles Lindbergh Blvd. Uniondale, NY 11553

SH2 Domains src, PLCγ, p85
agarose & western blotting reagents
Quantitative ELISA’s
TGFα, EGF-R, pantropic p53
Phosphatases 1B & T Cell
84th Annual Meeting of the
AMERICAN ASSOCIATION FOR CANCER RESEARCH
May 19-22, 1993 Orlando, FL

An Outstanding Scientific Program That Integrates the Most Recent Findings in Basic and Clinical Cancer Research

SCIENTIFIC SESSIONS

Minority Issues Committee Symposium: Careers and Opportunities in Cancer Research - Jerome W. Williams, Sarah Antonia Li, Jacqueline Locklear, Eddie Reed, Denny Jones, Jr., Paulette S. Gray, Roberto Villarreal.

Richard and Hinda Rosenthal Foundation Award Lecture
Wuon Ki Hong.

Plenary Session: Predicting the Impact of Molecular Biology on Cancer Therapy in the 21st Century (Joint AACR/ASCO)
Stephen H. Friend, Frank McCormick, Christopher Walsh, Judah Folkman.

Symposium: Cytokines in the Immunomodulation of Cancer
Elizabeth A. Grimm, Walter Fiers, Bernd Gansbacher, James J. Mullo, Jerome Rizzi.

Symposium: Molecular Mechanisms of Drug Resistance
Jane L. Biedler, George R. Stark, Peter W. Meulara, Susan P. C. Ljuta, Janis C. Donnon.

Presidential Address - Lee W. Wattenberg.

Plenary Session: From Bench to Clinic: Concepts in the Design and Targeting of New Chemotherapeutic Agents
Bruce A. Chabner, Susan E. Baur, Beverly S. Mitchell, Robert C. Jackson, Yuri G. Pommier, Anthony E. Pegg.


Symposium: Nitric Oxide and Superoxide: Endogenous Modulators of DNA Damage - Steven R. Tannenbaum, Larry K. Keffer, Michael A. Marletta, John M. Essigmann, Bruce Demaille.


Bruce M. Cain Award Lecture - Victor Ling.

American Cancer Society Award Lecture - Joseph F. Fraumeni, Jr.

Methods Workshop: Clinical Research Methodology - Brigid G. Lennihan, Steven Piantadosi, Barry E. Storer, Stephen L. George, Jane E. Henney. (Additional registration fee required.)


G. H. A. Clowes Memorial Award Lecture - Stuart H. Yuhas.


Symposium: Biology and Treatment of Pediatric Cancer


Symposium: Late Advances in Tumor Suppressor Genes Edward E. Harlow, Tyler Jacks, Daniel A. Haber, Jon Hrubetz, Ann Bowcock.

C. P. Rhoads Memorial Award Lecture - Tom Curran.

Fri. Afternoon May 21

Public Education Session - Speaker to be announced.

Symposium: Vitamin D and Cancer - Michael B. Sporn, Hector F. DeLuca, John A. Erasmus, Michael Holick, Thomas A. Brazeius.

Symposium: Advances in Molecular Epidemiology of Human Cancer - Curtis S. Harris, Robert F. Murray, Jr., Frederica Perera, David Sirodknys, Yasuko Nakamura.

Symposium: Molecular Basis for the Modulation of Radiation Sensitivity - W. Gillus, McKenna, David A. Button, Michael B. Kastan, Ruth J. Mcachel, Ralph H. Beischelbaum, Peter M. Meach.

Symposium: Protein Kinase C: Modulator of the Cancer Phenotype and Target for Chemotherapy - Peter M. Blumberg, Robert M. Bell, Michael Kariu, I. Bernard Weinstein, Stuart H. Yagi.

Sat. Morning May 22

Symposium: Immunologic Approaches to Targeted Therapy - Ira Pasan, Lee M. Nadler, David M. Goldberg, Peter D. Senter.


Methods Workshop: Embryonic Stem Cells and Gene Knockouts - Thomas C. D'Orsborn, Kirk Thomas, Mark Moyer, Beverly Koller. (Additional registration fee required.)

Minitssymposia, poster discussion sessions, and regular poster sessions will be organized from over 3,400 submitted papers in all areas of cancer research.

SESSIONS OF PROPPERED PAPERS

G~ERAL INFORMATION

FEES

Member Registration
Nonmember Registration (includes Proceedings)
$115a
P~$210

Proceeding Student and Associate Member Registration
$55**
Workshop Registration
$90
Proceedings of the AACR
$35

*$25 discount for advance registration received by March 29, 1993.

**$10 discount for advance registration received by March 29, 1993.

PUBLICATIONS

The Proceedings of the American Association for Cancer Research contains abstracts of all papers accepted for presentation by the Program Committee and extended abstracts of symposium presentations and special lectures. The Proceedings is received by all members with paid-up subscriptions to AACR journals, or it may be purchased at the time of registration for $35.

The Program of the Annual Meeting of the American Association for Cancer Research is included in the registration fee.

Detailed listings of available positions and prospective candidates will be available for consultation during the Annual Meeting and will be published in the Annual Proceedings and in two issues of the Association's journal Cancer Research. Invitations will be scheduled in Orlando.

EXHIBIT SHOW

Displays by over 100 firms offering the most up-to-date products, services, and publications for both basic and clinical cancer researchers.

Upjohn Awards

For presenters of meritorious abstracts as selected by the Program Committee. No formal application necessary. Predoctoral students, postdoctoral fellows, and physicians in training are eligible. Upjohn Company sponsors awards to investigators in North America: Upjohn International, Inc., to investigators in other countries.

Comprehensive Minority Biomedical Program of the National Cancer Institute

For predoctoral students, postdoctoral fellows, or physicians in training in the U.S. and Canada from minority groups that have been traditionally underrepresented in cancer research.

WICR SESSIONS

Women in Cancer Research will organize several sessions during the meeting that will be of interest to all registrants.

Advance Registration (includes advance mailing of Program and Proceedings)
March 29, 1993
Hotel Reservations
April 16, 1993
Special fares available on Delta Air Lines and Continental Airlines through Utiliglobe Travel, 800-243-4370 (from U.S. and Canada only) or 215-629-0046 (in PA).

Budget Rent a Car 800-772-3773 Account Number VARIACR

INFORMATION AND FORMS

American Association for Cancer Research
Public Ledger Building
620 Chestnut Street, Suite 816
Philadelphia, PA 19106-3483
215-440-9300 FAX: 215-440-9373
AMERICAN ASSOCIATION FOR CANCER RESEARCH
SCIENTIFIC CONFERENCES: 1993-1994

APRIL 13-17, 1993
Genetic Control of Cell Growth
Laureates Conference
General Motors
Cancer Research Foundation
Chairpersons: Leland H. Hartwell, Seattle, WA;
Peter K. Vogt, Los Angeles, CA; George F.
Vande Woude, Frederick, MD
San Luis Hotel, Galveston, TX

MAY 19-22, 1993
84th Annual Meeting
Chairperson: Michael B. Sporn, Bethesda, MD
Orange County Convention Center, Orlando, FL

OCTOBER 17-21, 1993
Cell Death and Cancer
Chairperson: Alan R. Eastman, Hanover, NH
Chatham Bars Inn, Chatham (Cape Cod), MA

NOVEMBER 7-11, 1993
Molecular Approaches to Cancer Immunotherapy
Chairperson: Ralph A. Reisfeld, San Diego, CA
Grove Park Inn, Asheville, NC

NOVEMBER 9-13, 1993
Interactions of Cancer Susceptibility Genes and Environmental Carcinogenesis
Joint Meeting with International Agency for Research on Cancer
Chairpersons: Frederick P. Li, Boston, MA, and Ruggero Montesano, Lyon, France
IARC, Lyon, France

DECEMBER 5-9, 1993
Cell Signalling and Cancer Treatment
Joint Meeting with British Association for Cancer Research and European Organisation for Research and Treatment of Cancer (PAM Group)
Chairpersons: Garth Powis, Tucson, AZ;
Paul Workman, Glasgow, Scotland
El San Juan Hotel, San Juan, PR

JANUARY 17-22, 1994
Risk Assessment in Environmental Carcinogenesis
Chairpersons: Philip C. Hanawalt, Stanford, CA;
James A. Swenberg, Chapel Hill, NC
Whistler Resort and Conference Center, Whistler, B.C., Canada

JANUARY 31-FEBRUARY 5, 1994
Molecular Genetics of Progression and Metastasis
Chairperson: Lance A. Liotta, Bethesda, MD
Big Sky Resort, Big Sky, MT

FEBRUARY 19-24, 1994
Genomic Instability and Cancer
Chairpersons: Thea D. Tiusty and Lawrence A. Loeb
Banff Springs Hotel, Banff, Alberta, Canada

MARCH 5-11, 1994
Growth Factors, Development, and Cancer
Joint Meeting with Friedrich-Miescher Institut
Chairpersons: Harold L. Moses and Bernd Groner
Congress Center, Interlaken, Switzerland

APRIL 10-13, 1994
85th Annual Meeting
Chairperson: Karen S.H. Antman, Boston, MA
Moscone Center, San Francisco, CA

AACR members will receive brochures on the above special conferences as soon as they are available. Nonmembers should call or write:
American Association for Cancer Research
Public Ledger Building
620 Chestnut Street, Suite 816
Philadelphia, PA 19106-3483
215-440-9300 • 215-440-9313 (FAX)
INTERACTIONS OF CANCER SUSCEPTIBILITY GENES AND ENVIRONMENTAL CARCINOGENS

Joint Meeting Organized by the American Association for Cancer Research (AACR) and the International Agency for Research on Cancer (IARC)

November 9-13, 1993
Lyon, France

CONFERENCE CHAIRPERSONS
Frederick P. Li / Boston, USA
Ruggero Montesano / Lyon, France

SCIENTIFIC PROGRAM

Introductory Lectures
Curtis C. Harris / Bethesda, USA
Lorenzo Tomatis / Lyon, France
Lee W. Wattenberg / Minneapolis, USA
Manfred F. Rajewsky / Essen, Germany

Genetic Instability
Kari K. Alitalo / Helsinki, Finland
T. Heidmann / Paris, France
Thea D. Tlsty / Chapel Hill, USA

Experimental Models of Genetic Susceptibility
J. Carl Barrett / Research Triangle Park, USA
Henry C. Piot / Madison, USA
Bernard M. Mecher / Heidelberg, Germany

DNA Damage and Repair
Dirk Bootsma / Rotterdam, The Netherlands
John M. Essigmann / Cambridge, USA
Mutsuo Sekiguchi / Fukuoka, Japan

Mechanisms of Transgenerational Carcinogenesis
Carmen Sapienza / La Jolla, USA
Ulrike Wintersberger / Vienna, Austria
David Malkin / Toronto, Canada
Christopher J. Kemp / Glasgow, Scotland

Human Cancers
Frederick P. Li / Boston, USA
Valerie Beral / Oxford, England
Bruce A. J. Ponder / Cambridge, England
Neil E. Caporaso / Bethesda, USA
Gilbert M. Lenoir / Lyon, France

Markers of Individual Exposure
Ruggero Montesano / Lyon, France
Peter A. Cerutti / Epalinges, Switzerland

Opportunities for Prevention
I. Bernard Weinstein / New York, USA

Information and Application Forms
American Association for Cancer Research
Public Ledger Building
620 Chestnut Street, Suite 816
Philadelphia, PA 19106-3483
(215) 440-9300
(215) 440-9313 (FAX)
THE AMERICAN ASSOCIATION FOR CANCER RESEARCH PRESENTS

An Important Educational Opportunity for
Predoctoral and Postdoctoral Fellows
Contemplating Careers in Basic Cancer Research

HISTOPATHOBIOLOGY OF NEOPLASIA

The Edward A. Smuckler Memorial Workshop
Supported by a Generous Grant from the National Cancer Institute

Keystone Conference Center
Keystone, Colorado
June 20 - June 27, 1993

- Intensive training in the histopathology and biology of neoplasia.
- Twenty-eight hours of hands-on laboratory exercises directed by distinguished pathologists.
- An outstanding series of lectures on rapidly developing areas of cancer research by laboratory directors and other prominent investigators.
- Extensive written course materials that will serve as valuable references in the future.
- Full funding of participants' lodging and subsistence expenses during the workshop.

LABORATORY AND LECTURING FACULTY

John M. Lehman*, Albany College of Medicine, Albany, NY, **Course Director**
Stephen Baird*, VA Medical Center, San Diego, CA
Helen Feiner, New York University School of Medicine, New York, NY
Michael W. Lieberman*, Baylor College of Medicine, Houston, TX
Robert Low, University of Colorado School of Medicine, Denver, CO
Gary Miller*, University of Colorado School of Medicine, Denver, CO
Harold L. Moses, Vanderbilt University School of Medicine, Nashville, TN

Sharon B. Murphy, Children's Hospital, Chicago, IL
G. Barry Pierce, University of Colorado School of Medicine, Denver, CO.
Michael Prystowsky, University of Pennsylvania School of Medicine, Philadelphia, PA
Stewart Sell, University of Texas Medical School, Houston, TX
Saraswati Sukumar, The Salk Institute, La Jolla, CA
Frederick Waldman, University of California, San Francisco, CA
Sandra R. Wolman*, Harper Hospital, Detroit, MI

*Member of the Workshop Executive Committee

APPLICATION DEADLINE: APRIL 30, 1993

Further Information: American Association for Cancer Research • Public Ledger Building • 620 Chestnut Street • Suite 816 • Philadelphia, PA 19106-3483
Telephone: (215) 440-9300 • FAX: (215) 440-9313
The current interest in tamoxifen as a tool in the prevention and treatment of human breast cancer brings to the fore a pioneer in the study of the endocrine functions and therapeutic action of this drug. Featured on the cover of this issue is V. Craig Jordan, Professor of Human Oncology and Pharmacology at the University of Wisconsin-Madison and Director of the Breast Cancer Program of that school's Comprehensive Cancer Center. Dr. Jordan has contributed much to the basic and clinical research that has resulted in the wide usage of tamoxifen in the treatment of primary breast cancer. His work has helped to define the antiestrogenic actions of tamoxifen and has led to its current use in adjuvant therapy. Of major importance is the action of the drug to prevent secondary occurrences of primary breast cancer; by lowering the odds that high-risk individuals will contract the disease, tamoxifen may act as a preventive agent.

Dr. Jordan's role in the development of tamoxifen has been recognized by the Susan G. Komen Breast Cancer Foundation, which in 1992 chose him as the recipient of the inaugural Brinker International Breast Cancer Award for Basic Research for his pharmacological investigations into the antiestrogenic and antitumor actions of the drug. In addition, he was recently presented with the Gaddum Memorial Award, the highest prize of the British Pharmacological Society, for tamoxifen development, and he is scheduled to receive an award this fall from the American Society for Pharmacology and Experimental Therapeutics for his contributions to the field of experimental therapeutics. In 1989, Dr. Jordan was honored, along with Dr. L. J. Lerner, by the American Association for Cancer Research (AACR) with the Eighth Cain Memorial Award given annually to an individual or research team for outstanding preclinical research leading to the improved care of cancer patients.

Dr. Jordan graduated from the University of Leeds in 1969 and earned the Ph.D. from the same university in 1972 for studies on antiestrogen action. From 1972 to 1978, while training with E. V. Jensen and the late W. L. McGuire, he held positions at the Worcester Foundation for Experimental Biology and at the University of Leeds. At the former institute, he initiated the first laboratory studies on the antitumor action of tamoxifen. In 1979/1980, he served as Director of the Endocrinology Unit of the Ludwig Institute for Cancer Research in Bern, Switzerland. In 1980, Dr. Jordan was appointed Assistant Professor of Oncology and Human Pharmacology at the University of Wisconsin; he was named Professor in 1985 and accepted his current position in 1987.


Dr. Jordan is active in chemical, pharmacological, and endocrinological associations, and he plays a major role in the training of graduate and postdoctoral students. Currently a Managing Editor of Cancer Letters, he serves on many editorial boards, including those of Cancer Research, the Journal of the National Cancer Institute, Breast Cancer Research and Treatment, and the European Journal of Cancer.

Sidney Weinhouse